Moonlake Immunotherapeutics Stock Performance
| MLTX Stock | USD 54.43 0.19 0.35% |
On a scale of 0 to 100, MoonLake Immunotherapeuti holds a performance score of 7. The company secures a Beta (Market Risk) of 2.07, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MoonLake Immunotherapeuti will likely underperform. Please check MoonLake Immunotherapeuti's value at risk, as well as the relationship between the kurtosis and market facilitation index , to make a quick decision on whether MoonLake Immunotherapeuti's current price movements will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in MoonLake Immunotherapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, MoonLake Immunotherapeuti showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.35 | Five Day Return 2.52 | Year To Date Return (8.60) | Ten Year Return 418.88 | All Time Return 418.88 |
1 | Disposition of 10000 shares by Kristian Reich of MoonLake Immunotherapeuti at 60.15 subject to Rule 16b-3 | 09/16/2024 |
2 | MoonLake Immunotherapeutics Trading Down 4 | 09/17/2024 |
3 | MoonLake Immunotherapeutics Short Seller Sentiment is Bearish On This ADR Stock | 09/23/2024 |
4 | MoonLake Immunotherapeutics Shares Acquired by Marshall Wace LLP - MarketBeat | 09/26/2024 |
5 | Disposition of 171000 shares by Sturge Simon of MoonLake Immunotherapeuti at 53.72 subject to Rule 16b-3 | 10/04/2024 |
6 | Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics | 10/09/2024 |
7 | This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50 | 10/24/2024 |
8 | MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - TipRanks | 11/08/2024 |
9 | FMR LLCs Strategic Acquisition of MoonLake Immunotherapeutics Shares | 11/13/2024 |
10 | MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - MSN | 11/20/2024 |
| Begin Period Cash Flow | 39.5 M |
MoonLake |
MoonLake Immunotherapeuti Relative Risk vs. Return Landscape
If you would invest 4,631 in MoonLake Immunotherapeutics on September 3, 2024 and sell it today you would earn a total of 812.00 from holding MoonLake Immunotherapeutics or generate 17.53% return on investment over 90 days. MoonLake Immunotherapeutics is currently generating 0.3017% in daily expected returns and assumes 3.1629% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than MoonLake, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MoonLake Immunotherapeuti Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MoonLake Immunotherapeuti's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MoonLake Immunotherapeutics, and traders can use it to determine the average amount a MoonLake Immunotherapeuti's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0954
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MLTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.16 actual daily | 28 72% of assets are more volatile |
Expected Return
| 0.3 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average MoonLake Immunotherapeuti is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MoonLake Immunotherapeuti by adding it to a well-diversified portfolio.
MoonLake Immunotherapeuti Fundamentals Growth
MoonLake Stock prices reflect investors' perceptions of the future prospects and financial health of MoonLake Immunotherapeuti, and MoonLake Immunotherapeuti fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MoonLake Stock performance.
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 2.94 B | ||||
| Shares Outstanding | 63.06 M | ||||
| Price To Book | 7.03 X | ||||
| EBITDA | (54.11 M) | ||||
| Net Income | (44.08 M) | ||||
| Cash And Equivalents | 92.71 M | ||||
| Cash Per Share | 2.51 X | ||||
| Total Debt | 3.81 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 25.51 X | ||||
| Book Value Per Share | 7.74 X | ||||
| Cash Flow From Operations | (42.78 M) | ||||
| Earnings Per Share | (1.27) X | ||||
| Market Capitalization | 3.43 B | ||||
| Total Asset | 526.54 M | ||||
| Retained Earnings | (116.66 M) | ||||
| Working Capital | 504.2 M | ||||
About MoonLake Immunotherapeuti Performance
Evaluating MoonLake Immunotherapeuti's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if MoonLake Immunotherapeuti has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MoonLake Immunotherapeuti has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 87.4 K | 77.7 K | |
| Return On Tangible Assets | (0.07) | (0.07) | |
| Return On Capital Employed | (0.10) | (0.10) | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | (0.07) | (0.07) |
Things to note about MoonLake Immunotherapeuti performance evaluation
Checking the ongoing alerts about MoonLake Immunotherapeuti for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MoonLake Immunotherapeuti help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MoonLake Immunotherapeuti had very high historical volatility over the last 90 days | |
| Net Loss for the year was (44.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| MoonLake Immunotherapeutics currently holds about 92.71 M in cash with (42.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.51. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - MSN |
- Analyzing MoonLake Immunotherapeuti's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MoonLake Immunotherapeuti's stock is overvalued or undervalued compared to its peers.
- Examining MoonLake Immunotherapeuti's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MoonLake Immunotherapeuti's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MoonLake Immunotherapeuti's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MoonLake Immunotherapeuti's stock. These opinions can provide insight into MoonLake Immunotherapeuti's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.